Aquestive Therapeutics, Inc. AQST United States — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s united states — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s united states — revenue?
- Aquestive Therapeutics, Inc. (AQST) reported united states — revenue of $13.25M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s united states — revenue changed year-over-year?
- Aquestive Therapeutics, Inc.'s united states — revenue increased by 154.7% year-over-year, from $5.2M to $13.25M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s united states — revenue?
- Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s united states — revenue has grown at a -8.8% compound annual growth rate (CAGR), from $42.86M to $29.6M.
- What does united states — revenue mean?
- This metric represents the total gross sales generated from pharmaceutical products and licensing activities within the United States market. It serves as a primary indicator of the company's commercial footprint and market penetration for its specialized oral film product portfolio in its domestic region. Tracking this revenue stream helps investors assess the performance of the company's core commercial operations and its ability to capture market share in the U.S. healthcare sector.